Clinical Trial Search

Primary: Percentage of Participants That Preferred Phenylephrine HCl 30 mg Extended Release Tablets, as Compared to Phenylephrine HCl 10 mg Immediate Release Tablets for the…

Primary: Non-inferiority of Aliskiren 300 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP) — -11.63; -9.19 mm Hg

Primary: Overall Survival Time — 9.2; 11.0 Months — p=0.017

Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure to Week 12 — -13.96; -11.64 mm Hg

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) to Week 24 — -1.28; -1.18 Percent of Glycosylated Hemoglobin

Primary: Frequency of Adverse Events — 38; 1; 1; 24 participants

Primary: Number of Seroconverted Subjects for Anti-human Papillomavirus (HPV)-16 and 18 Antibodies — 130; 4; 190; 5 Participants

Primary: Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study — -10.99; -8.95; -7.23 mm Hg

Primary: Analgesic Efficacy, as Measured by the Sum of Pain Intensity Differences (SPID) Scale — 14.80; 0.40 Units on a scale — p=<0.0001

Primary: Clinical Cure at the Day 4 (EOT)/Exit Visit — 62.5; 50.6 percentage of subjects

Primary: Pregnancy Rate (Expressed as Pearl Index) for Women 18 to 45 Years Old, MITT Population — 1.823; 2.978 Pearl Index

Primary: Mean Number of Metaphase II Oocytes Per Participant Who Underwent Ovum Pick up for Intra-cytoplasmic Sperm Injection (ICSI) — 9.5 Metaphase II Oocytes

Primary: Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for >= 26 Weeks (182 Days) — 3; 20; 23 Participants — p=<0.001

Primary: Estimated Annualized Aggregate Relapse Rate (ARR) — 0.16; 0.18; 0.40 Relapses per year

Primary: Mean Change From Baseline in Best-corrected Visual Acuity of the Study Eye at Month 12 — 4.9; 3.8; 8.3 letters